TMCnet News
Research and Markets: Opportunity Analyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/fpztpk/opportunityanalyze) has announced the addition of the "Opportunity Analyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018" report to their offering. Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled proliferation of B lymphocytes (a type of white blood cell) in the bone marrow, blood and lymphoid tissues. This report focuses on the current treatment landscape, unmet needs, pipeline and commercial opportunity in the CLL market with coverage of both the first-line and relapsed/refractory settings. While the current standard of care consists of chemoimmunotherapy, CLL disease management is poised for dramatic changes, particularly in the treatment of relapsed/refractory and elderly patients, as four new drugs (Gazyva, Imbruvica, idelalisib and IPI-145) will launch during the forecast period. Key Questions Answered
Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Epidemiology 6 Current Treatment Options 7 Unmet Needs Assessment and Oppportunity Analysis 8 R&D Strategies 9 Pipeline Assessment 10 Pipeline Valuation Analysis 11 Appendix For more information visit http://www.researchandmarkets.com/research/fpztpk/opportunityanalyze
|